Question

A 62-year-old male with unresectable cholangiocarcinoma is planned for systemic therapy. Which regimen forms the current standard first-line chemotherapy for advanced disease?

• A. FOLFOX regimen
• B. Gemcitabine + Cisplatin
• C. Capecitabine + Oxaliplatin
• D. Sorafenib monotherapy

Hint:

Targeted therapies are rapidly evolving for cholangiocarcinoma. Always remember to check for actionable mutations:
IDH1 mutations (target: Ivosidenib).
FGFR2 fusions (target: Pemigatinib, Infigratinib).

Answer 1

The Correct Option is B

Concept:
Cholangiocarcinoma is a malignant tumor arising from the epithelial cells of the bile ducts.
The majority of patients present with advanced, unresectable, or metastatic disease, necessitating systemic palliative chemotherapy to improve survival and quality of life.
The question tests knowledge of the universally accepted standard-of-care first-line systemic chemotherapy regimen for this cancer.
Explanation:
• The landmark Phase III ABC-02 (Advanced Biliary Tract Cancer) trial firmly established the standard of care for advanced cholangiocarcinoma.

• This trial demonstrated a significant overall survival and progression-free survival advantage for the combination of Gemcitabine and Cisplatin over Gemcitabine monotherapy.

• Therefore, the doublet chemotherapy regimen of Gemcitabine plus Cisplatin (GemCis) has been widely adopted worldwide as the preferred first-line systemic treatment.

• Recently, the addition of immunotherapy (like Durvalumab or Pembrolizumab) to the Gemcitabine + Cisplatin backbone has shown further survival benefits (TOPAZ-1 trial), solidifying the GemCis backbone's importance.

• Option (A), FOLFOX (5-fluorouracil, leucovorin, oxaliplatin), is utilized extensively in colorectal cancer and serves as a second-line option for biliary tract cancers after the failure of GemCis (based on the ABC-06 trial).

• Option (C), Capecitabine + Oxaliplatin (CAPOX), is also generally used for gastrointestinal malignancies like colorectal or gastric cancers but is not the first-line standard for cholangiocarcinoma.

• Option (D), Sorafenib, is a tyrosine kinase inhibitor primarily used as a systemic treatment for advanced Hepatocellular Carcinoma (HCC), not cholangiocarcinoma.
Final answer:
The combination of Gemcitabine and Cisplatin is the standard first-line chemotherapy regimen for advanced cholangiocarcinoma.